Jamie Kudera

People over 70 better tolerate radiation therapy to hormonal therapy according to results from the phase III clinical trial EUROPA.

Promising ctDNA study to help understand risk of recurrence in TNBC and BRCA-positive early breast cancer ends due to low enrollment. This discontinued study suggests potential for liquid biopsy to guide treatment and offers takeaways for future research.

Adding palbociclib to standard treatment results in average of 44.3 months without cancer growth or spread in HER2-positive, HR-positive metastatic breast cancer.

Active monitoring may be a safe option for some people with low-risk DCIS, according to early results from the COMET study. At two years, outcomes were similar to treatment, but more follow-up is needed.

Imlunestrant proves effective against hormone receptor-positive, HER2-negative advanced breast cancer in the EMBER3 trial.

People with breast cancer need more information and, in some cases, better research around sexuality, physical activity, diet, and dietary supplements including cannabis.

Dose optimization is a reform effort that challenges the traditional “more is better” approach to cancer drug dosing.

First prospective study of pregnancy after breast cancer highlights need to expand access to fertility preservation.

Patient care needs to be equitable—and to consider the whole person.

Women who consumed a diet rich in fruits and vegetables and got regular exercise lost 13% of their weight over six months.

Promising targeted therapy fails to meet clinical trial goals in metastatic breast cancer.

Progression was delayed by five months in hormone receptor-positive, HER2-low, and HER2-ultralow MBC compared with chemo, suggesting that even a very small amount of HER2 expression matters.

Treating hormone receptor-positive, HER2- advanced or metastatic breast cancer with abemaciclib resulted in six months of progression-free survival compared with 5.3 months in non-abemaciclib group.

Inavolisib results likely lead to new standard treatment option for hormone receptor-positive, HER2-negative, metastatic breast cancer.

At the 2024 Conference on Metastatic Breast Cancer, Maryam Lustberg, MD, MPH, addressed new and emerging treatments, clinical trials, future trends, and unmet needs in metastatic breast cancer (MBC)

The cancer care community needs targeted approaches to help people with cancer avoid financial distress and stay healthier longer.

Randomized control trial shows benefit of exercise for people with metastatic breast cancer

Immunotherapy/chemotherapy combination kills cancer cells before surgery in early-stage, ER+/HER2- breast cancer

Read More

 | 3 Min. Read |   1

Antibody drug conjugate outperformed chemotherapy and improved quality of life for people with HR+, HER2- metastatic breast cancer

Study results offer new option for people with locally advanced or metastatic HER2-positive breast cancer that has spread to the brain

New drug for certain metastatic HR+ breast cancers generally well tolerated according to quality-of-life study

Read More

 | 2 Min. Read |   1

A trial presented at the 2023 ASCO meeting studied the antibody drug conjugate patritumab deruxtecan

Read More

 | 4 Min. Read |   1

Much-awaited results of a clinical trial presented at the annual meeting of the American Society of Clinical Oncology on June 5, 2023 support the use of telephone-based coaching to promote weight loss in women with breast cancer.

Presentations focus on peripheral neuropathy, hair loss and scalp cooling, medical marijuana, and integrative care

Read More

 | 6 Min. Read |   1

A new study challenges the use of a CDK 4/6 inhibitor (CDK4/6i) as a first treatment for hormone-receptor positive (HR+) advanced breast cancer.

People with early-stage hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer will soon have a new treatment option in ribociclib (Kisqali), now used to treat metastatic HR+, HER2- breast cancer.

The chemotherapy drug capecitabine (Xeloda) is often used to treat breast cancer, but for some people it can be hard to tolerate. New research reveals that diclofenac, an easily available topical gel, can help prevent one of the most challenging side effects that can happen with capecitabine.

When used with chemotherapy, the monoclonal antibody drug outperformed chemotherapy alone in people with stage IV, metastatic, or recurrent TNBC.

A review of multiple studies shows benefit of ovarian function suppression or ablation for young women with early-stage, estrogen receptor-positive breast cancer or who were at risk of breast cancer recurrence.

Low-dose tamoxifen, or “Babytam,” can prevent breast cancer recurrence among people with high-risk lesions, such as those with DCIS, LCIS, or atypical ductal hyperplasia

Results from Living Beyond Breast Cancer’s 2022 needs assessment show more focus needed on side effects

Participants with HR-positive metastatic breast cancer saw no benefit from adding the CDK inhibitor but a small group who also got immunotherapy had a longer period without disease growth

An investigational genomic test for POLAR status predicts those most likely to benefit from radiation therapy

Capivasertib on track for possible FDA approval in metastatic hormone receptor-positive disease

Patient advocates drive discussion of race, call for action at the 2022 San Antonio Breast Cancer Symposium (SABCS)

Pausing hormone therapy results in healthy pregnancies and babies for most women

The SABCS 2022 opening session highlighted how talking about key topics early improves quality of life for people living with metastatic breast cancer

Elacestrant is poised to move forward as a new option for metastatic hormone receptor-positive, HER2-negative  breast cancer in 2023. New results point to a relationship between the drug’s effectiveness and both the prior length of time on CDK 4/6 inhibitors and the presence of an ESR1 mutation.

Read More

 | 5 Min. Read |   1

Two studies support use of trastuzumab deruxtecan for metastatic HER2-positive breast cancer 

New findings from two studies presented at SABCS confirm abemaciclib plus endocrine therapy reduces risk of recurrence, while adding everolimus does not improve outcomes 

Several studies presented at the 2022 Annual Meeting of the American Society of Clinical Oncology focused on ways to better tailor treatment for premenopausal women with early-stage breast cancer, especially those with hormone receptor-positive breast cancer.

Hormonal therapy alone following surgery may be enough to prevent local recurrence in some people with early-stage hormone receptor-positive breast cancer, according to research presented at the 2022 annual meeting of the American Society of Clinical Oncology.

At the annual meeting of the American Society of Clinical Oncology, a panel of three researchers and a physician on June 3, 2022 shared findings and strategies to address the changing needs of older people with breast and other cancers. Their take-away: now is the time to join the conversation.

Read More

 | 7 Min. Read |   1

More than 80% of Black people with metastatic breast cancer are somewhat or very likely to participate in a clinical trial, yet only 40% report having a conversation with their health care team about them, according to new patient-led research.

Read More

 | 9 Min. Read |   2

At a special session on gender-based and sexual orientation inequities at the 2022 gathering of the American Society for Clinical Oncology (ASCO), advocates discussed the challenges LGBTQ+ people face in cancer prevention and treatment and strategies to address them.

A study presented at the 2022 meeting of the American Society of Clinical Oncology of trastuzumab deruxtecan or TDX-d (Enhertu) is very likely to change the standard of care for many people with metastatic breast cancer.

The CDK 4/6 inhibitor palbociclib (Ibrance) did not extend overall survival when combined with hormonal therapy as a first-line treatment in people with hormone-receptor positive, HER2-negative metastatic breast cancer, according to a presentation at the 2022 meeting of the American Society of Clinical Oncology.

Read More

 | 7 Min. Read |   10

Thanks to a new federal law, the No Surprises Act, people with breast cancer are less likely to receive surprise medical bills.

Black women were three-and-a-half times more likely to develop lymphedema than white women following treatment for breast cancer, according to results of a prospective study presented at the San Antonio Breast Cancer Symposium on December 10.

Early results of a quality-of-life study presented at the 2021 San Antonio Breast Cancer Symposium found that olaparib did not worsen or prolong side effects when given after chemotherapy for BRCA+, HER2-, high-risk, early-stage breast cancer.

Health disparities in breast cancer care proved to be an important part of the 2021 San Antonio Breast Cancer Symposium, especially the session on “Trust in Science," which brought together advocates, doctors, and researchers concerned about racial equity in cancer treatment.

Research presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) identified a new standard second-line treatment for metastatic disease, a more effective tyrosine kinase inhibitor, and a cell pathway for further study in HER2-positive breast cancer.

Aromatase inhibitors are more effective than tamoxifen in preventing cancer from coming back if ovarian function is suppressed, according to research presented in two sessions at the 2021 San Antonio Breast Cancer Symposium (SABCS).

Read More

 | 5 Min. Read |   1

Elacestrant, an endocrine therapy taken in pill form, emerges as a new option for people with ER+/HER2- metastatic breast cancer, according to an update on the EMERALD clinical trial presented at the 2021 San Antonio Breast Cancer Symposium.

The results from the much-anticipated phase III PALLAS trial, presented at the 2021 San Antonio Breast Cancer Symposium, show that palbociclib (Ibrance) does not improve outcomes for people with early-stage hormone-positive (HR+) HER2- breast cancer.

The first day of the 2021 San Antonio Breast Cancer Symposium (SABCS) included findings from two clinical trials that show the immunotherapy drug pembrolizumab (Keytruda) offers a new treatment option for people with triple-negative breast cancer.

Read More

 | 5 Min. Read |   1